Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma

被引:19
作者
Bevilacqua, P
Verderio, P
Barbareschi, M
Bonoldi, E
Boracchi, P
Palma, PD
Gasparini, G
机构
[1] ST BARTOLO REG MED CTR,DEPT ONCOL,I-36100 VICENZA,ITALY
[2] UNIV MILAN,INST MED STAT & BIOMETRY,MILAN,ITALY
[3] ST CHIARA MED CTR,TRENT,ITALY
关键词
breast cancer; immunocytochemistry; Ki-S1; antibody; prognosis; proliferation markers;
D O I
10.1007/BF01806494
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
In a series of 205 node-negative breast cancers (NNBC), we determined staining by the novel antibody Ki-S1, a marker of tumor cell proliferation, in order to test its association with other prognostic variables and its prognostic significance. Ki-S1 was determined in routinely formalin-fixed paraffin-embedded tumor samples. Ki-S1 gave a nuclear staining in the majority of the carcinomas (188 of 205), with percentages of reacting nuclei ranging from 2% to 90% (median value of 7%). In 107 tumors frozen sections were available to also assess the Ki-67 antibody. Among these, 94 had a nuclear staining of cancer cells ranging from 5% to 80% (median value of 7%). In 46 tumors we also determined the MIB-1 antibody. The percentage of MIB-1 nuclear staining ranged from 1% to 50% (median value of 20%). There was no significant relationship between Ki-S1 and the other two cell kinetic markers. Ki-S1 labeling was significantly associated only with tumor size (p = 0.03). With a median follow-up of 6 years, Ki-S1 had no significant prognostic value for either relapse-free survival (RFS) or overall survival (OS)(Ki-S1 as continuous logarithmic variable; p = 0.86 and p = 0.23, respectively). For RFS the following variables had a significant prognostic value: Ki-67 (less than or equal to 10% vs > 10%;p = 0.037); progesterone receptor (PgR) expression (- vs +/++; p = 0.041); tumor size (pn vs pT2-3; p = 0.042) and grading (GI vs GII-III; p = 0.047). For OS, tumor size (p = 0.0044), age (continuous variable; p = 0.0060), and Ki-67 (p = 0.043) were significantly prognostic. In multivariate analysis (final model), only tumor size retained a significant and independent prognostic value for RFS (p = 0.0042). For OS, both tumor size (p = 0.0029) and age (less than or equal to 55 years vs > 55 years; p = 0.041) retained significance in the multivariate model. In conclusion, Ki-S1 does not seem to have prognostic relevance in this series of NNBC. Possible hypotheses to explain this observation are discussed.
引用
收藏
页码:123 / 133
页数:11
相关论文
共 34 条
[1]
DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS [J].
ALTMAN, DG ;
LAUSEN, B ;
SAUERBREI, W ;
SCHUMACHER, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :829-835
[2]
IMMUNOHISTOCHEMICAL DEMONSTRATION OF ESTROGEN-RECEPTORS (ER) IN FORMALIN-FIXED, PARAFFIN-EMBEDDED HUMAN-BREAST CANCER-TISSUE BY USE OF A MONOCLONAL-ANTIBODY TO ER [J].
ANDERSEN, J ;
ORNTOFT, TF ;
POULSEN, HS .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1988, 36 (12) :1553-1560
[3]
[Anonymous], 1983, APPL STAT
[4]
QUANTITATIVE GROWTH FRACTION EVALUATION WITH MIBI AND KI67 ANTIBODIES IN BREAST CARCINOMAS [J].
BARBARESCHI, M ;
GIRLANDO, S ;
MAURI, FM ;
FORTI, S ;
ECCHER, C ;
MAURI, FA ;
TOGNI, R ;
DALLAPALMA, P ;
DOGLIONI, C .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 102 (02) :171-175
[5]
IMMUNOCYTOCHEMICAL DETECTION OF PROGESTERONE-RECEPTOR BY MONOCLONAL KD-68 ANTIBODY IN OPERABLE BREAST-CANCER - CORRELATIONS WITH BIOCHEMICAL ASSAY, PATHOLOGICAL FEATURES AND CELL PROLIFERATIVE RATE [J].
BEVILACQUA, P ;
PEA, M ;
GASPARINI, G .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (11) :1595-1602
[6]
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[7]
HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[8]
KI-S1, A NOVEL PROLIFERATIVE MARKER - FLOW CYTOMETRIC ASSESSMENT OF STAINING IN HUMAN BREAST-CARCINOMA CELLS [J].
CAMPLEJOHN, RS ;
BROCK, A ;
BARNES, DM ;
GILLETT, C ;
RAIKUNDALIA, B ;
KREIPE, H ;
PARWARESCH, MR .
BRITISH JOURNAL OF CANCER, 1993, 67 (04) :657-662
[9]
MONOCLONAL-ANTIBODIES AGAINST RECOMBINANT PARTS OF THE KI-67 ANTIGEN (MIB-1 AND MIB-3) DETECT PROLIFERATING CELLS IN MICROWAVE-PROCESSED FORMALIN-FIXED PARAFFIN SECTIONS [J].
CATTORETTI, G ;
BECKER, MHG ;
KEY, G ;
DUCHROW, M ;
SCHLUTER, C ;
GALLE, J ;
GERDES, J .
JOURNAL OF PATHOLOGY, 1992, 168 (04) :357-363
[10]
PREDICTION OF RELAPSE OR SURVIVAL IN PATIENTS WITH NODE-NEGATIVE BREAST-CANCER BY DNA FLOW-CYTOMETRY [J].
CLARK, GM ;
DRESSLER, LG ;
OWENS, MA ;
POUNDS, G ;
OLDAKER, T ;
MCGUIRE, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (10) :627-633